{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T19:35:09Z","timestamp":1784230509507,"version":"3.55.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100027715","name":"NW Children's Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100027715","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018369","name":"RE Children\u2019s Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018369","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013061","name":"Jilin Provincial Scientific and Technological Development Program","doi-asserted-by":"publisher","award":["20220101284JC"],"award-info":[{"award-number":["20220101284JC"]}],"id":[{"id":"10.13039\/501100013061","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.leukres.2024.107547","type":"journal-article","created":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T16:29:05Z","timestamp":1719246545000},"page":"107547","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Combining the novel FLT3 and MERTK dual inhibitor MRX-2843 with venetoclax results in promising antileukemic activity against FLT3-ITD AML"],"prefix":"10.1016","volume":"144","author":[{"given":"Shuangshuang","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangbing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Gai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maik","family":"H\u00fcttemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhuai","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey W.","family":"Taub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yubin","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2024.107547_bib1","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1002\/cncr.22233","article-title":"Acute myeloid leukemia: epidemiology and etiology","volume":"107","author":"Deschler","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2024.107547_bib2","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","author":"Cancer Genome Atlas Research","year":"2013","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.leukres.2024.107547_bib3","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1182\/blood.2021011583","article-title":"Follow-up of patients with R\/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial","volume":"139","author":"Perl","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107547_bib4","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.1200\/JCO.22.00602","article-title":"Venetoclax plus gilteritinib for FLT3-mutated relapsed\/refractory acute myeloid leukemia","volume":"40","author":"Daver","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2024.107547_bib5","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.85630","article-title":"The MERTK\/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia","volume":"1","author":"Minson","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.leukres.2024.107547_bib6","doi-asserted-by":"crossref","first-page":"5359","DOI":"10.1038\/onc.2013.40","article-title":"Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia","volume":"32","author":"Lee-Sherick","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.leukres.2024.107547_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/cells11172752","article-title":"Inhibition of Mcl-1 synergistically enhances the antileukemic activity of gilteritinib and MRX-2843 in preclinical models of FLT3-mutated acute myeloid leukemia","volume":"11","author":"Wu","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.leukres.2024.107547_bib8","doi-asserted-by":"crossref","first-page":"6815","DOI":"10.1158\/1078-0432.CCR-19-0832","article-title":"Inhibition of Bcl-2 synergistically enhances the antileukemic activity of midostaurin and gilteritinib in preclinical models of FLT3-mutated acute myeloid leukemia","volume":"25","author":"Ma","year":"2019","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.leukres.2024.107547_bib9","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s10495-022-01756-7","article-title":"c-Myc plays a critical role in the antileukemic activity of the Mcl-1-selective inhibitor AZD5991 in acute myeloid leukemia","volume":"27","author":"Liu","year":"2022","journal-title":"Apoptosis"},{"key":"10.1016\/j.leukres.2024.107547_bib10","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/s41408-021-00502-7","article-title":"The combination of CUDC-907 and gilteritinib shows promising in vitro and in vivo antileukemic activity against FLT3-ITD AML","volume":"11","author":"Qiao","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.leukres.2024.107547_bib11","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/jcph.821","article-title":"Pharmacokinetics of venetoclax, a novel BCL-2 inhibitor, in patients with relapsed or refractory chronic lymphocytic leukemia or non-hodgkin lymphoma","volume":"57","author":"Salem","year":"2017","journal-title":"J. Clin. Pharm."},{"key":"10.1016\/j.leukres.2024.107547_bib12","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.18.01600","article-title":"Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib\/II study","volume":"37","author":"Wei","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2024.107547_bib13","first-page":"13","article-title":"Detection of mycoplasma contaminations","volume":"290","author":"Uphoff","year":"2005","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.leukres.2024.107547_bib14","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1038\/leu.2014.72","article-title":"Acute myeloid leukemia cells harboring MLL fusion genes or with the acute promyelocytic leukemia phenotype are sensitive to the Bcl-2-selective inhibitor ABT-199","volume":"28","author":"Niu","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2024.107547_bib15","article-title":"Mechanisms responsible for the synergistic antileukemic interactions between ATR inhibition and cytarabine in acute myeloid leukemia cells","volume":"7","author":"Ma","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.leukres.2024.107547_bib16","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1182\/blood.V87.8.3395.bloodjournal8783395","article-title":"Enhanced metabolism of 1-beta-D-arabinofuranosylcytosine in Down Syndrome cells: A contributing factor to the superior event free survival of Down Syndrome children with acute myeloid leukemia","volume":"87","author":"Taub","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107547_bib17","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0145-2126(96)00132-4","article-title":"The human bladder carcinoma cell line 5637 constitutively secretes functional cytokines","volume":"21","author":"Quentmeier","year":"1997","journal-title":"Leuk. Res"},{"key":"10.1016\/j.leukres.2024.107547_bib18","doi-asserted-by":"crossref","first-page":"5499","DOI":"10.1158\/1078-0432.CCR-10-1707","article-title":"Mechanisms of synergistic antileukemic interactions between valproic acid and cytarabine in pediatric acute myeloid leukemia","volume":"16","author":"Xie","year":"2010","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.leukres.2024.107547_bib19","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharm. Rev."},{"key":"10.1016\/j.leukres.2024.107547_bib20","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1093\/jnci\/dji026","article-title":"GATA1, cytidine deaminase, and the high cure rate of Down syndrome children with acute megakaryocytic leukemia","volume":"97","author":"Ge","year":"2005","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.leukres.2024.107547_bib21","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2005-06-2219","article-title":"Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia","volume":"107","author":"Ge","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107547_bib22","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.3324\/haematol.2018.201343","article-title":"Antileukemic activity and mechanism of action of the novel PI3K and histone deacetylase dual inhibitor CUDC-907 in acute myeloid leukemia","volume":"104","author":"Li","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2024.107547_bib23","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.bcp.2017.11.022","article-title":"Targeting PI3K, mTOR, ERK, and Bcl-2 signaling network shows superior antileukemic activity against AML ex vivo","volume":"148","author":"Su","year":"2018","journal-title":"Biochem Pharm."},{"key":"10.1016\/j.leukres.2024.107547_bib24","doi-asserted-by":"crossref","first-page":"6099","DOI":"10.1111\/jcmm.13886","article-title":"Inhibition of XPO1 enhances cell death induced by ABT-199 in acute myeloid leukaemia via Mcl-1","volume":"22","author":"Luedtke","year":"2018","journal-title":"J. Cell Mol. Med"},{"key":"10.1016\/j.leukres.2024.107547_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0079106","article-title":"Panobinostat enhances cytarabine and daunorubicin sensitivities in AML cells through suppressing the expression of BRCA1, CHK1, and Rad51","volume":"8","author":"Xie","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.leukres.2024.107547_bib26","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41392-020-0112-3","article-title":"Inhibition of CDK9 by voruciclib synergistically enhances cell death induced by the Bcl-2 selective inhibitor venetoclax in preclinical models of acute myeloid leukemia","volume":"5","author":"Luedtke","year":"2020","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.leukres.2024.107547_bib27","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"10.1016\/j.leukres.2024.107547_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.115283","article-title":"Co-targeting of HDAC, PI3K, and Bcl-2 results in metabolic and transcriptional reprogramming and decreased mitochondrial function in acute myeloid leukemia","volume":"205","author":"Hege Hurrish","year":"2022","journal-title":"Biochem Pharm."},{"key":"10.1016\/j.leukres.2024.107547_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0037699","article-title":"Mitochondrial structure, function and dynamics are temporally controlled by c-Myc","volume":"7","author":"Graves","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.leukres.2024.107547_bib30","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1158\/2159-8290.CD-15-0507","article-title":"MYC, metabolism, and cancer","volume":"5","author":"Stine","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.leukres.2024.107547_bib31","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/ncb2488","article-title":"Anti-apoptotic MCL-1 localizes to the mitochondrial matrix and couples mitochondrial fusion to respiration","volume":"14","author":"Perciavalle","year":"2012","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.leukres.2024.107547_bib32","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1038\/sj.cdd.4402165","article-title":"Bcl-2 induces pro-oxidant state by engaging mitochondrial respiration in tumor cells","volume":"14","author":"Chen","year":"2007","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.leukres.2024.107547_bib33","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.stem.2012.12.013","article-title":"BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells","volume":"12","author":"Lagadinou","year":"2013","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.leukres.2024.107547_bib34","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.3324\/haematol.2021.278369","article-title":"AXL\/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill FLT3-ITD acute myeloid leukemia","volume":"107","author":"Post","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2024.107547_bib35","doi-asserted-by":"crossref","first-page":"18782","DOI":"10.1073\/pnas.0810199105","article-title":"Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction","volume":"105","author":"Wise","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.leukres.2024.107547_bib36","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1182\/blood.2021013201","article-title":"The STAT3-MYC axis promotes survival of leukemia stem cells by regulating SLC1A5 and oxidative phosphorylation","volume":"139","author":"Amaya","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107547_bib37","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/nature07823","article-title":"c-Myc suppression of miR-23a\/b enhances mitochondrial glutaminase expression and glutamine metabolism","volume":"458","author":"Gao","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2024.107547_bib38","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1182\/blood-2017-12-820035","article-title":"Glutaminolysis is a metabolic dependency in FLT3(ITD) acute myeloid leukemia unmasked by FLT3 tyrosine kinase inhibition.","volume":"131","author":"Gallipoli","year":"2018","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212624001139?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212624001139?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T22:43:27Z","timestamp":1736203407000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212624001139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":38,"alternative-id":["S0145212624001139"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2024.107547","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combining the novel FLT3 and MERTK dual inhibitor MRX-2843 with venetoclax results in promising antileukemic activity against FLT3-ITD AML","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2024.107547","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107547"}}